DUBLIN–(BUSINESS WIRE)–The “North America Extra Corporeal Membrane Oxygenation (ECMO) System Market 2019-2028” report has been added to ResearchAndMarkets.com’s offering.
North American extra corporeal membrane oxygenation (ECMO) system market is expected to flourish at a CAGR of 4.85% over the estimated period 2019-2028.
The United States and Canada together constitute the North American extra corporeal membrane oxygenation (ECMO) system market.
The extra corporeal membrane oxygenation system market in the United States is witnessing considerable growth owing to the high incidence of cardiovascular diseases as well as respiratory diseases. In response to the potential treatment of the widespread pandemic COVID-19, the US FDA (Food and Drug Administration) issued guidelines to expand the availability of devices, used for ECMO.
According to the NCT (National Clinical Trials Registry), researchers from British Columbia are working towards increasing the survival rate of cardiac arrests with the establishment of ECMO-CPR treatment. Besides, extra corporeal membrane oxygenation has reduced a considerable number of deaths as a temporary alternative to lung transplant. All these factors are expected to boost the studied market growth in the United States.
In Canada, the extra corporeal membrane oxygenation (ECMO) is gaining traction as an efficient therapy option by clinical professionals. Several initiatives have been implemented in the country to increase awareness about its benefits. Due to all these factors, the extra corporeal membrane oxygenation (ECMO) system market in Canada is expected to experience growth over the forecast years.
Some noteworthy companies in the extra corporeal membrane oxygenation (ECMO) system market are Hemovent Gmbh, LivaNova Plc, Xenios AG (Fresenius SE & Co KGaA), Spectrum Medical, Nipro Corporation, ALung Technologies Inc and Eurosets.
Key Topics Covered:
1. North America Extra Corporeal Membrane Oxygenation (ECMO) System Market – Summary
2. Industry Outlook
2.1. Market Definition
2.2. Porter’s Five Forces Model
2.3. Impact of Covid-19 on ECMO System Market
2.4. Market Attractiveness Index
2.5. Vendor Scorecard
2.6. Key Insights
2.7. Market Drivers
2.7.1. Rising Popularity of ECMO Technology
2.7.2. Increasing Prevalence of Chronic Disorders
2.8. Market Restraints
2.8.1. Significant Cost of ECMO Systems
2.8.2. Existence of Alternative Techniques
2.9. Market Opportunities
2.9.1. Growing Awareness Regarding Applications of ECMO Systems
2.9.2. Advancement in Technology
2.10. Market Challenges
2.10.1. Lack of Specialized Skills for Operation
2.10.2. Risks Associated With ECMO Procedures
3. Extra Corporeal Membrane Oxygenation (Ecmo) System Market Outlook – by Application
3.3. Extracorporeal Cardiopulmonary Resuscitation (Ecpr)
4. Extra Corporeal Membrane Oxygenation (Ecmo) System Market Outlook – by Modality
4.3. Other Modalities
5. Extra Corporeal Membrane Oxygenation (Ecmo) System Market – North America
5.1. United States
6. Company Profiles
6.1. Hemovent GmbH
6.2. Livanova plc
6.3. Microport Scientific Corporation
6.4. Terumo Medical Corporation
6.5. Elsius Biomedical Inc
6.6. Abbott Laboratories
6.7. Alung Technologies Inc
6.9. Spectrum Medical
6.10. Xenios AG (Fresenius SE & Co KGAA)
6.11. Medtronic plc
6.12. Getinge Ab
6.13. Nipro Corporation
6.14. Origen Biomedical Inc
7. Research Methodology & Scope
For more information about this report visit https://www.researchandmarkets.com/r/7uxqns